Neuronox | Medica Aesthetic & Medical Solutions

What is Neuronox?

Neuronox, a neurotoxin derived from Clostridium botulinum, is a popular medical-grade product used in aesthetic medicine. Its key ingredient is purified botulinum toxin complex, comprising neurotoxin and associated proteins. This potent formulation acts by temporarily blocking the release of acetylcholine, a neurotransmitter, at the neuromuscular junction. By doing so, Neuronox effectively relaxes targeted muscles, reducing the appearance of dynamic wrinkles and fine lines.

When administered by trained healthcare professionals via intramuscular injections, Neuronox exhibits precise and localized action. Its composition ensures consistent potency, allowing for accurate dosage and optimal results. By temporarily inhibiting muscle contractions, Neuronox helps patients achieve a more youthful and refreshed appearance.

Neuronox's effectiveness and safety have been extensively studied and validated in clinical trials. Its carefully selected ingredients and rigorous manufacturing processes ensure quality and reliability. Overall, Neuronox offers a trusted solution for individuals seeking to address facial wrinkles and rejuvenate their appearance.

Indication and Usage

Neuronox is indicated for the temporary improvement of facial wrinkles, specifically in the glabellar lines (frown lines) and lateral canthal lines (crow's feet).

1 .

Administered via intramuscular injections into the targeted muscles.
2 .

Recommended dosage and injection technique may vary depending on the patient's individual needs and desired outcome.
3 .

Effects typically become noticeable within a few days after treatment, with maximum results observed within two weeks.
4 .

The duration of Neuronox's effects varies among patients but generally lasts for approximately three to six months.
5 .

Benign essential blepharospasm
6 .

Equinus foot deformities brought on by several glabellar lines linked to corrugator and/or procerus muscle activity.
7 .

Upper limb spasticity caused by a stroke.
8 .

Temporarily improve moderate to severe lateral canthal lines linked to orbicularis oculi activity.
9 .

Adults who have cervical dystonia

Each vial contains:

Clostridium botulinum toxin type A as the active component
Human serum albumin as a stabilizer
Sodium chloride, an isotonic agent

Key Benefits

Safety

as it has undergone rigorous testing and clinical trials, establishing its safety profile in aesthetic procedures. It is more stable and has a more lasting effect than other comparable products thanks to its distinct formulation and manufacturing process.

Suitability

for a wide range of patients seeking temporary improvement in facial wrinkles, such as glabellar lines and crow's feet. Because Neuronox contains less protein than other botulinum toxin type A products, it is less likely to cause a patient's immune system to respond negatively. This means that patients who have previously experienced adverse reactions to other brands of botulinum toxin type A may find it to be a particularly suitable option.

Versatility

as it can be customized to address specific areas of concern, providing precise and targeted muscle relaxation. For instance, it is successful in treating chronic migraines, cervical dystonia, and even bladder dysfunction.

Non-surgical alternative

to improve the appearance of wrinkles, eliminating the need for invasive procedures.

Natural-looking results

By temporarily reducing muscle activity, Neuronox helps create smoother and more youthful-looking skin without sacrificing facial expression or mobility.

Quick and convenient injections

typically taking just a few minutes and allowing patients to resume their daily activities shortly after treatment with minimal downtime.

Temporary effects

providing patients with flexibility in deciding if and when to repeat treatments based on their desired outcomes.

Patient satisfaction

Many patients report high levels of satisfaction with Neuronox treatments due to its effectiveness in reducing the appearance of wrinkles and rejuvenating their facial appearance.

Clinical Assessment

Study Design.

A Phase III clinical trial that is double-blind, randomized, and active-controlled. After receiving 20 U of either Neuronox® or Ona-BoNT/A in a 1:1 ratio, 314 patients were randomly assigned to one of the two groups. FWS was then used to assess whether the glabellar frown lines had improved.
Primary Efficacy Endpoint

The responder rate was calculated based on the investigator's real-time evaluation of the maximum frown lines at Week 4.
Safety Endpoint

The investigator and subject's reports of AE signs and symptoms, as well as the findings of physical exams and laboratory tests.

About Medytox

Botulinum toxin type A Meditoxin® (trade names: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc®, and Meditoxin®) was introduced in 2006, and since then, Medytox has experienced rapid expansion. Since 2009, Medytox has held close to 40% of the market in Korea, and with the addition of various indications, this share is predicted to rise even further.

With a significant market share in the global botulinum market, Medytox is astounding the world. They intend to launch the currently being developed new type of botulinum toxin products along with exceeding 10% of the market share in the global market with the aim of breaking into the US and European markets. By setting ambitious goals for the global market, Medytox will become the biopharmaceutical sector's leader in the coming years.